Economics and Aging: Retirement Income of Women Sixty-five and Older

This study is undertaken to investigate the effects of work history patterns, human capital factors and sociodeaographic characteristics on incoae and assets of women 65 years of age and over. A nationally representative sample is used in the study. The research tests race, marital status and age for interaction with independent variables. The results of the study are discussed in terms of the income sources and types of assets which women 65 years of age and over possess.Housing, Interior Design and Consumer Studie

The impact of coronavirus in education : some personal perspectives

This is the accepted version of the article by Joanne Smith, Associate Teaching Professor, Divisional Lead for Health, Community and Early Years, and Patricia Donovan, Practice Trainer, both at Faculty of Health and Wellbeing, University of Bolton. Published in British Journal of Healthcare Assistants,© 2020 MA Healthcare Ltd. The published article can be found at the link above

Bone mineral density in women with premature ovarian insufficiency with and without the use of low dose hormone therapy

Orientadores: Cristina Laguna Benetti Pinto, Rose Luce Gomes do AmaralDissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciências MédicasResumo: Introdução: Insuficiência Ovariana Prematura 46XX (IOP) é um estado de hipogonadismo, caracterizado por oligoamenorréia, infertilidade e deficiência estrogênica em mulheres abaixo de 40 anos. Mulheres com IOP deveriam ser tratadas com reposição estrogênica até pelo menos a idade da menopausa, para reduzir os sinais e sintomas do hipoestrogenismo e se possível, preservar a massa mineral óssea. Objetivos: Avaliar se Terapia Hormonal (TH) com baixa dose estrogênica é adequada para reduzir a perda de massa óssea de mulheres com IOP. Métodos: Estudo de corte transversal. Foram avaliadas 239 mulheres com IOP: 132 usando TH baixa dose (17-Beta-Estradiol 1mg + Noretisterona ou estrogênio conjugado 0,625mg + acetado de Medroxiprogesterona) e 107 mulheres sem TH. Todas responderam anamnese detalhada (idade, idade na última menstruação e idade no início de tratamento) e foram submetidas a avaliação de densidade mineral óssea (DMO) na coluna lombar (CL), colo femoral (CF) e fêmur total (FT) através da técnica DEXA. Resultados: As médias de idade, idade na última menstruação e de IMC para o grupo sem tratamento e para o grupo com TH foram 38,1 ± 6,1 e 36,8 ± 7,3 anos; 31,4 ± 7,3 e 30,7 ± 7,2 anos; 26,6 ± 7,1 e 25,8 ± 4,6, respectivamente (p=NS). A DMO média na CL foi 1,06 ± 0,15 e 1,00 ± 0,17g/cm2 (p=0,003), para CF 0,92 ± 0,15 e 0,89 ± 0,14 (p=0,0479) e FT de 0,92 ± 0,19 e 0,91 ± 0,13 g/cm2 (p=0,039), respectivamente para os grupos. Verificou-se DMO alterada na CL em 45,1% (35,2% Osteopenia e 9,8% Osteoporose) das mulheres sem tratamento e 60,1% (38,1 Osteopenia e 22% Osteoporose) quando usavam TH baixa dose (p=0,01). No CF 25,4% (21,5% Osteopenia e 3,9% Osteoporose) das mulheres sem tratamento e 29,6% (22,8% Osteopenia e 6,7% Osteoporose) quando usavam TH baixa dose (p=0,38) mostravam alteração e, para FT, em 32,35% (19,6% Osteopenia e 12,7% Osteoporose) das sem tratamento e 36,4% (21,2% Osteopenia e 15,2% Osteoporose) para TH de baixa dose (p=0,34). Conclusão: A TH de baixa dose não parece ser adequada para reduzir a perda de massa óssea de coluna lombar, colo de fêmur e fêmur total em mulheres com IOPAbstract: Introduction: Premature Ovarian Insufficiency (POI) is a hypogonadism state, characterized by oligoamenorhea, infertility and estrogen deficiency in women below the age of 40. Women with POI should be treated with estrogen replacement until at least the age of menopause, in order to reduce the signs and symptoms of hypoestrogenism and if possible, preserve bone mineral density (BMD). Aim: To assess whether hormone therapy (HT) with low estrogen dose is sufficient to avoid bone mass loss in women with POI. Methods: Cross-sectional study. Two hundred and thirty nine women were evaluated: 132 using low dose TH (1 mg of 17-Beta-Oestradiol + Norethisterone or 0.625 mg of conjugated estrogen + medroxyprogesterone acetate) and 107 women without HT. Detailed history was obtained from the studied women (age, age of last menstrual period and age of onset of treatment) and were subjected to evaluation of bone mineral density (BMD) in the lumbar spine (LS), femoral neck (FN) and total femur (TF) through DEXA technique. Results: The mean age, age at last menstrual period and BMI for the untreated group and the group with HT were 38.1 ± 6.1 and 36.8 ± 7.3 years; 31.4 ± 7.3 and 30.7 ± 7.2 years; 26.6 ± 7.1 and 25.8 ± 4.6 respectively (p = NS). The mean LS BMD was 1.06 ± 0.15 and 1.00 ± 0,17g / cm2 (p = 0.003), CF 0.92 ± 0.15 and 0.89 ± 0.14 (p = 0.0479) and FT 0.92 ± 0.19 and 0.91 ± 0.13 g / cm2 (p = 0.039) respectively for the groups. BMD at LS was compromised in 45.1% (35.2% osteopenia and osteoporosis 9.8%) for women without treatment and 60.1% (38.1% osteopenia and 22% osteoporosis) low dose HT (p = 0.01). For the FN 25.4% (21.5% Osteopenia and Osteoporosis 3.9%) of women without treatment and 29.6% (22.8% Osteopenia and Osteoporosis 6.7%) for the ones in use of TH low dose, were compromised (p = 0 38). For TF compromise was found in 32.35% (19.6% osteopenia and 12.7% osteoporosis) of the untreated women and 36.4% (21.2% and 15.2% osteoporosis osteopenia) for low dose HT (p = 0.34). Conclusion: The low dose HT seems to be inadequate to reduce bone loss in the lumbar spine, femoral neck and total femur in women with IOPMestradoFisiopatologia GinecológicaMestra em Ciências da Saúd

Brief Communication

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/67313/2/10.1177_088307389801300308.pd

Robust Weak-lensing Mass Calibration of Planck Galaxy Clusters

In light of the tension in cosmological constraints reported by the Planck team between their SZ-selected cluster counts and Cosmic Microwave Background (CMB) temperature anisotropies, we compare the Planck cluster mass estimates with robust, weak-lensing mass measurements from the Weighing the Giants (WtG) project. For the 22 clusters in common between the Planck cosmology sample and WtG, we find an overall mass ratio of \left = 0.688 \pm 0.072. Extending the sample to clusters not used in the Planck cosmology analysis yields a consistent value of $\left< M_{Planck}/M_{\rm WtG} \right> = 0.698 \pm 0.062$ from 38 clusters in common. Identifying the weak-lensing masses as proxies for the true cluster mass (on average), these ratios are $\sim 1.6\sigma$ lower than the default mass bias of 0.8 assumed in the Planck cluster analysis. Adopting the WtG weak-lensing-based mass calibration would substantially reduce the tension found between the Planck cluster count cosmology results and those from CMB temperature anisotropies, thereby dispensing of the need for "new physics" such as uncomfortably large neutrino masses (in the context of the measured Planck temperature anisotropies and other data). We also find modest evidence (at 95 per cent confidence) for a mass dependence of the calibration ratio and discuss its potential origin in light of systematic uncertainties in the temperature calibration of the X-ray measurements used to calibrate the Planck cluster masses. Our results exemplify the critical role that robust absolute mass calibration plays in cluster cosmology, and the invaluable role of accurate weak-lensing mass measurements in this regard.Comment: 5 pages, 2 figure